Compare Gilead Sciences, Inc. (GILD) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Global Clean Energy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.89 (market cap $168.35B), while iShares Global Clean Energy ETF trades at $18.4. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals.
| GILD | ICLN | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $23.75 |
52-Week Low | $110.56 | $13.66 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
ICLN is trading at $18.395, up 1.74% today, with a bearish technical signal from moving averages. The ETF provides exposure to 105 global renewable energy companies but faces competition from traditional energy ETFs offering lower fees and higher yields. Recent news highlights clean energy's 25% gains in 2026, though policy uncertainties and geopolitical tensions pose risks.
The outlook remains mixed with structural growth in clean energy demand balanced against regulatory headwinds and expense ratio disadvantages. Key opportunities include global energy transition trends, while risks involve U.S. permit delays and Chinese supply chain tensions affecting solar development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
